Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma 

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice. 

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer

Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the role of RNA and the formation of liquid droplet structures within cancer cells.

Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement

Clinical Pearls and Future Directions in AL Amyloidosis

Videos

Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.

Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.

AL Amyloidosis: Background, Patient Profile, and Staging

Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.

Navigating the Differential Diagnosis of AL Amyloidosis

Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.

Treatment Approaches in AL Amyloidosis 

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Limitations of Available Treatment Options for Patients with Cardiac Involvement 

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab Safety Profile in the VITAL Study

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Adverse Event Management in AL Amyloidosis

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Clinical Pearls and Future Directions in AL Amyloidosis

EP: 1.AL Amyloidosis: Background, Patient Profile, and Staging

EP: 2.Navigating the Differential Diagnosis of AL Amyloidosis

EP: 3.Treatment Approaches in AL Amyloidosis

EP: 4.Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP: 5.Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP: 6.Birtamimab Safety Profile in the VITAL Study

EP: 7.Adverse Event Management in AL Amyloidosis

EP: 8.Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP: 9.Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP: 10.Clinical Pearls and Future Directions in AL Amyloidosis

Latest Conference Coverage